Plain-English translation of NCT07235202 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , a new medication, works better when combined with standard chemotherapy drugs for pancreatic cancer patients whose cancer has continued to grow despite their first course of treatment. Researchers are testing different doses of the medication to find the safest and most effective combination. The goal is to understand whether this treatment approach can slow or shrink the cancer and improve how long patients survive.
Pancreatic cancer is very difficult to treat, and patients whose cancer comes back after initial chemotherapy have limited options. This trial exists to see whether adding this medication to standard chemotherapy can give these patients a better chance of response and longer survival.
You likely qualify if…
You likely don't qualify if…
You would receive weekly intravenous infusions of the medication combined with standard chemotherapy drugs, either in the initial dose-finding phase or the expansion phase of the trial. The trial has two parts testing different chemotherapy combinations, and you'll be assigned to one based on eligibility and the trial's progress. You'll have regular visits for blood tests, imaging scans, and physical exams to monitor how your cancer responds and how well you tolerate the treatment.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
China